XML 45 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary Of Significant Accounting Policies - Additional Information (Detail)
$ / shares in Units, € in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 28, 2014
USD ($)
Sep. 03, 2014
USD ($)
Jan. 30, 2014
USD ($)
Sep. 04, 2013
USD ($)
Jan. 22, 2013
USD ($)
Apr. 06, 2007
shares
Sep. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
Investment
$ / shares
shares
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
$ / shares
shares
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Investment
Segment
$ / shares
shares
Dec. 31, 2015
EUR (€)
Segment
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Dec. 31, 2013
USD ($)
$ / shares
shares
Summary Of Significant Accounting Policies [Line Items]                                      
Common stock, shares purchased through issuance of warrants | shares           150,000                          
Warrant term           7 years                          
Revenue recognized                               $ 2,115,000      
Non-refundable up-front payment                               2,000,000      
Payment to be received upon signing of agreement                               125,675      
Revenue recognized under revenue recognition, up front payment                             $ 2,000,000        
Royalty and other revenue                       $ 1,000,000 $ 125,000   1,991,000     $ 3,117,000 $ 20,687,000
Percentage of royalty revenue, remittance to the University of Michigan                                     15.00%
Cost of royalty revenue               $ 0 $ 0 $ 0 $ 0 0 0 $ 0 0       $ 2,682,000
Revenue from sponsored research and development projects                               $ 0   0 803,000
Long-term marketable securities, minimum original maturity term                               1 year 1 year    
Marketable securities, average remaining contractual maturity period                               5 months 24 days 5 months 24 days    
Number of debt securities in unrealized loss positions | Investment               34               34      
Debt securities in unrealized loss positions, total unrealized loss               $ 19,000               $ 19,000      
Debt securities in unrealized loss positions, total fair market value               12,520,000               12,520,000      
Credit risk               0               0      
Gain (loss) on investments                               0   0 0
Fair value of other assets               0               0      
Fair value of other liabilities               0               0      
Increase to milestone payment               1,969,000 $ 233,000 $ 768,000 $ 1,112,000 1,945,000 $ 10,000 $ 18,000 98,000 4,083,000   2,072,000 $ 91,000
Payment of contingent considerations                               99,000      
Reserves for excess and obsolete inventory               $ 343,000       $ 78,000       $ 343,000   $ 78,000  
Stock options, outstanding | shares               1,240,935       1,225,117       1,240,935   1,225,117 1,610,988
Stock options, weighted average exercise price | $ / shares               $ 10.44       $ 8.31       $ 10.44   $ 8.31 $ 5.07
Common stock excluded from calculation of diluted earnings per share | shares                               196,209 196,209 307,475 187,000
Number of operating segment | Segment                               1 1    
Long Lived Assets               $ 42,985,000       $ 47,348,000       $ 42,985,000   $ 47,348,000  
Goodwill impairment                               0   0 $ 0
Amortization expense                               $ 1,600,000   $ 1,425,000 1,022,000
Employee Stock Option | Awards Granted to Non-Executive Level Employees                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Estimated forfeiture rates               8.00%       8.00%       8.00%   8.00%  
Employee Stock Option | Awards Granted to Executive Level Employees                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Estimated forfeiture rates               3.00%       3.00%       3.00%   3.00%  
Non-Employee Directors                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Estimated forfeiture rates                       0.00%           0.00%  
Singapore                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Long Lived Assets               $ 0       $ 0       $ 0   $ 0  
Minimum                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Short-term marketable securities, minimum original maturity term                               90 days 90 days    
Licensing Agreements | Scripps Research Institute                                      
Summary Of Significant Accounting Policies [Line Items]                                      
License Agreement, initial license fee                               $ 300,000      
Total future milestone payments                               $ 4,300,000      
Common stock, shares issued | shares                               87,464 87,464    
Common stock, shares issued value                               $ 300,000      
Common stock, shares purchased through issuance of warrants | shares                                   150,000  
Warrant term                                   7 years  
Technology Transfer                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Revenue recognized                             $ 0        
Estimated selling price               300,000               300,000      
Consideration allocated to transaction               11,000               11,000      
Royalty and other revenue             $ 125,675                        
Refine Technology, LLC                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Increase to milestone payment                               4,048,000      
Refine Technology, LLC | Milestone Payments                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Payment of contingent considerations                               1,000,000      
Bio Flash | Minimum                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Royalty payment                               110,000      
Novozymes Biopharma DK A/S Sweden Ab | Milestone Payments                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Payment of contingent considerations                               29,000 € 25    
Non-software License Arrangement | Pfizer Incorporation                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Upfront payment received under license agreement         $ 5,000,000                            
Milestone Payment $ 1,000,000     $ 1,000,000                              
Clinical Development                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Milestone Payment                               60,000,000      
Potential milestone payments to be received               60,000,000               $ 60,000,000      
Royalty term                               10 years 10 years    
Initial Commercial Sales                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Potential milestone payments to be received               $ 100,000,000               $ 100,000,000      
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Upfront payment received under license agreement     $ 2,000,000                                
Potential milestone payments to be received                       $ 160,000,000           $ 160,000,000  
Provision for refund                                   0  
Revenue recognized                                   $ 2,100,000  
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Milestone Payment   $ 125,675                                  
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Percentage relate to clinical development from Milestone payment                                   37.00%  
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Percentage relate to clinical development from Milestone payment                                   63.00%  
Orencia Royalties from Bristol                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Royalty and other revenue                                     17,881,000
Cost of royalty revenue                                     $ 2,682,000